News Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Market Closed - Australian S.E. Other stock markets 02:10:21 2024-04-16 am EDT			5-day change	1st Jan Change
6.8 ^AUD	-2.30%		-5.29%	+10.57%

Feb. 26	Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	MT
Feb. 25	Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MAYNE PHARMA REPORTS 1H FY24 RESULTS WITH A 43% INCREASE IN REVENUE TO A$188 MILLION AND $8 MILLION UNDERLYING EBITDA	Feb. 27	AQ
Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	Feb. 25	MT
Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024	Feb. 25
Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Transcript : Mayne Pharma Group Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 29	AQ
Mayne Pharma Group Limited Approves Election of Anne Lockwood	Nov. 29	CI
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	Nov. 29
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mayne Pharma Gets Go-Ahead for Resignation of EY as Auditor	Nov. 03	MT
MAYNE PHARMA PROVIDES UPDATE ON FIRST QUARTER 2024 TRADING AND OUTLOOK	23-10-19	AQ
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	23-10-17
Mayne Pharma Acquires Dermatological Medication	23-09-26	MT
Mayne Pharma Group Limited completed the acquisition of Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC.	23-09-24	CI
Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.	23-09-06	CI
Australian Shares Rebound Ahead of Central Bank Policy Meeting	23-09-04	MT
Mayne Pharma Group Purchasing Global Rights to Topical Treatment RHOFADE	23-09-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Summary

Filters